Cancer Breakthroughs 2020 Forms Collaborative Melanoma and Sarcoma Working Group to Accelerate Personalized Immunotherapy

Physicians And Researchers From Columbia University And UPMC To Collaborate On The Development Of Combination Immunotherapy Clinical Trial Protocols Informed By Comprehensive Genomic And Proteomic Profiling

Augments Recently Announced Pediatric Cancer, Breast Cancer, Head And Neck Cancer And Radiation Working Groups

CULVER CITY, Calif. – June 17, 2016 -  Cancer Breakthroughs 2020, the nation's most comprehensive cancer collaborative initiative, today announced the formation of the Melanoma and Sarcoma Working Group to accelerate molecular-informed immunotherapy trials. The team consists of physicians, researchers and oncology professors from across the nation who have come together to focus their collective wisdom and expertise on identifying and developing the most effective, cancer-directed immunotherapy treatments for patients with melanoma and sarcoma.

Experts within the group will collaborate to develop clinical trial protocols,carefully studying elements such as standard of care, comprehensive molecular analysis test factors (including whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry), patient selection and appropriate combination-immunotherapy approaches. 

“The establishment of the Melanoma and Sarcoma Working Group reinforces Cancer Breakthroughs 2020’s commitment to accelerate the war on cancer,” stated Patrick Soon-Shiong, MD, founder and CEO of NantWorks and leader of the Cancer Breakthroughs 2020 program. “Through the collaborative effort of these academic and industry thought leaders, we will be able to provide patients with Melanoma and Sarcoma with next-generation immunotherapy treatment. The momentum to establish national collaborative groups addressing all cancer types continues, and I am so pleased by the excitement Cancer Breakthroughs 2020 has generated in the academic and scientific community".

The Melanoma and Sarcoma Working Group will be chaired by Richard Carvajal, MD, Columbia University Medical Center, Director of Experimental Therapeutics and Director of the Melanoma Service, who will spearhead the team’s efforts with ongoing meetings, the development of protocols and continued expansion of the Working Group. 

Other esteemed members of the Working Group include:

·       Gary Schwartz, MD, Columbia University Medical Center, Division Chief, Hematology/Oncology, and Associate Director, Herbert Irving Comprehensive Cancer Center

·       John Kirkwood, MD, UPMC, Director, Melanoma and Skin Cancer Program

“As members of the Melanoma and Sarcoma Working Group, we want to share – and gather – new knowledge and understanding of how to better treat our patients,” stated John Kirkwood, MD, Director of the Melanoma and Skin Cancer Program at UPMC. “Collectively, we have the passion and the expertise to help accelerate the goal of winning the war on cancer.”                                                  

CANCER BREAKTHROUGHS 2020 Working Group Established to Date:

 

Pediatric Cancer Working Group

Breast Cancer Working Group

Head And Neck Cancer Working Group

Radiation And Immuno-Oncology Working Group

About Cancer Breakthroughs 2020

The Cancer Breakthroughs 2020 program is one of the most comprehensive cancer collaborative initiative launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational breakthroughs to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit www.cancerbreakthroughs2020.org and follow Cancer Breakthroughs 2020 on Twitter.  

About NantHealth

The Cancer Breakthroughs 2020 program is one of the most comprehensive cancer collaborative initiative launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational breakthroughs to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit www.cancerbreakthroughs2020.org and follow Cancer Breakthroughs 2020 on Twitter.

Media Contact

Jen Hodson

NantWorks

jhodson@nantworks.com

562-397-3639